Healthcare / Medical DevicesTaiwan
$124.00
+1.00 (+0.81%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 31% · confianza 25%
FCF escenarios
weak_data · normalized FCF $619.3M · quality 74.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$11.7B
P/E
8.3x
↓EV/EBITDA
5.9x
↓ROE
14.7%
↑Gross Margin
46.0%
↓Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-24.1%
FCF CAGR
-39.4%
FCF margin
14.3%
FCF / Net income
0.42x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.20B · net income $1.44B · FCF $602.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.20B | $4.20B | $4.64B | $4.81B | $9.63B |
| Net Income | $1.44B | $1.44B | $1.16B | $1.02B | $3.38B |
| EBITDA | $1.87B | $1.87B | $1.65B | $1.57B | $4.61B |
| EPS | — | — | 12.04 | 10.62 | 35.10 |
| Gross Margin | 46.0% | 46.0% | 44.3% | 43.1% | 58.7% |
| Operating Margin | 22.2% | 22.2% | 17.4% | 20.4% | 43.7% |
| Net Margin | 34.3% | 34.3% | 25.0% | 21.2% | 35.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.12 | 0.12 | 0.12 | 0.12 | 0.07 |
| Current Ratio | 2.73 | 2.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $602.2M | $602.2M | $619.3M | $1.06B | $2.70B |
| Returns | |||||
| ROE | 14.7% | 14.7% | 12.8% | 11.4% | 35.0% |
| Valuation | |||||
| P/E | 8.26 | 8.26 | 12.04 | 15.73 | 5.13 |
| EV/EBITDA | 5.90 | 5.90 | 7.64 | 8.58 | 3.09 |
| P/B | 1.22 | 1.22 | 1.54 | 1.80 | 1.79 |
| Growth & Yield | |||||
| Revenue Growth | -9.4% | -9.4% | -3.5% | -50.1% | — |
| EPS Growth | — | — | 13.4% | -69.7% | — |
| Dividend Yield | 8.0% | 8.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+4.5%
Start / end P/E
n/dx → n/dx
EPS bridge
12.04 → n/d
Residual
-3.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.